Biogen's Phase 3 Trial for Felzartamab in Kidney Transplant Rejection: Key Details and Implications

Biogen is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of felzartamab in treating late antibody-mediated rejection in kidney transplant recipients. The trial is ongoing and recruiting participants. A successful outcome could position felzartamab as a leading treatment in this niche market and enhance Biogen's competitive edge in the biopharmaceutical industry.